Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.63 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.63 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 6/20 | 0.55 |
| ▸ | PPARD | Q03181 | 6/20 | 0.55 |
| ▸ | PPARA | Q07869 | 6/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780784 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22OR51E2 | |
| SCHEMBL9186388 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22OR51E2 | |
| SCHEMBL20537125 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22OR51E2 | |
| SCHEMBL2780957 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22OR51E2 | |
| SCHEMBL9794734 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22OR51E2 | |
| SCHEMBL4389370 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22OR51E2 | |
| SCHEMBL10592204 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22OR51E2 | |
| SCHEMBL15054423 | 0.97 | TSHR (0.67) | TSHRLMNANFKB1PMP22OR51E2 | |
| SCHEMBL14357994 | 0.97 | LMNA (0.69) | TSHRLMNANFKB1PMP22OR51E2 | |
| SCHEMBL259198 | 0.97 | LMNA (0.69) | TSHRLMNANFKB1PMP22OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022727-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID | GENOMATICA INC (US) | 2023-01-26 | — | — | US | claimed |
| US-9580731-B2 | Methods of producing 7-carbon chemicals via c1 carbon chain elongation associated with coenzyme B synthesis | INVISTA NORTH AMERICA S.A.R.L. (US) | 2017-02-28 | — | — | US | claimed |
| CN-105189764-A | Methods of producing 7-carbon chemicals via C1 carbon chain elongation associated with coenzyme B synthesis | INVISTA TECH SARL | 2015-12-23 | — | — | CN | claimed |
| EP-2938736-A2 | METHODS OF PRODUCING 7-CARBON CHEMICALS VIA C1 CARBON CHAIN ELONGATION ASSOCIATED WITH COENZYME B SYNTHESIS | Invista Technologies S.A R.L. (CH) | 2015-11-04 | — | — | EP | claimed |
| US-20140193863-A1 | Methods Of Producing 7-Carbon Chemicals Via C1 Carbon Chain Elongation Associated With Coenzyme B Synthesis | INVISTA North America S.á r.I. (US) | 2014-07-10 | — | — | US | claimed |
| WO-2014105790-A2 | METHODS OF PRODUCING 7-CARBON CHEMICALS VIA C1 CARBON CHAIN ELONGATION ASSOCIATED WITH COENZYME B SYNTHESIS | INVISTA NORTH AMERICA S.A.R.L. (US) | 2014-07-03 | — | — | WO | claimed |
| WO-2026101867-A1 | PROCESS FOR PREPARING A MACROCYCLIC DIAMINE, INTERMEDIATES, AND CRYSTALLINE FORMS THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12577591-B2 | Microorganisms and methods for increasing co-factors | GENOMATICA, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | AGAIN BIO APS (DK) | 2026-01-29 | — | — | US | disclosed |
| US-12503711-B2 | Method of producing and processing diamines to a diamine free base using a carbonate intermediate and an engineered microorganism | GENOMATICA, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| CN-116023365-B | Ketohexokinase inhibitors and uses thereof | 轩竹生物科技股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-114728871-B | Microorganisms and methods for reducing byproducts | 基因组股份公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240141397-A1 | MICROORGANISMS AND METHODS FOR THE PRODUCTION OF BIOSYNTHESIZED TARGET PRODUCTS HAVING REDUCED LEVELS OF BYPRODUCTS | AGAIN BIO APS (DK) | 2024-05-02 | — | — | US | disclosed |
| US-20120028320-A1 | PREPARATION OF ADIPIC ACID | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | disclosed |
| CN-102317464-A | From alpha-ketoacid biosynthesizing difunctionality alkane | CELEXION LLC | 2012-01-11 | — | — | CN | disclosed |
| CN-102307872-A | BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBOTT LAB | 2012-01-04 | — | — | CN | disclosed |
| CN-101910142-A | The conditioning agent of amyloid beta | HOFFMANN LA ROCHE | 2010-12-08 | — | — | CN | disclosed |
| US-7780801-B2 | for soldering flip chip surfaces; fluxing agent comprises keto acid such as levulinic acid or acetylbutyric acid; mixture of tacky solvent (ethoxylated glycerol) with non-tacky solvent (methanol) | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100175790-A1 | New Flux Composition and Process For Use Thereof | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20080124568-A1 | New flux composition and process for use thereof | GLOBALFOUNDRIES INC. (KY) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | DDC, DAO, ODC1 | TSHR 3382/4885LMNA 2536/4885NFKB1 2164/4885 |
| US-12577591-B2 | Microorganisms and methods for increasing co-factors | ABAT, HADHB, MMAB | TSHR 4263/4885LMNA 1752/4885NFKB1 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.